George Mendenhall, MD
Cardiovascular Disease · la Jolla, CANPI 1699925545
Payments from drug & device makers
Across 349 payments — averaging $309.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$54K
- Abbott$45K
- Boston Scientific$4K
- Biotronik Inc.$927
- Cvrx, Inc.$614
- Pfizer$531
- plus $3K from 27 others
What the payments were for
- Consulting fees$65,87079%
- Speaking & faculty fees$2,2503%
- Travel & lodging$6,1527%
- Food & beverage$8,93511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 64 | $53,885 |
| Abbott | 62 | $45,319 |
| Boston Scientific | 44 | $3,734 |
| Biotronik Inc. | 8 | $927 |
| Cvrx, Inc. | 16 | $614 |
| Pfizer | 23 | $531 |
| Novartis | 33 | $530 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $444 |
| Johnson & Johnson | 12 | $324 |
| Biosense Webster, Inc. | 3 | $260 |
| E.r. Squibb & Sons, L.L.C. | 12 | $225 |
| Philips North America LLC | 4 | $190 |
| Sanofi-aventis U.S. LLC | 5 | $122 |
| Impulse Dynamics (USA) Inc. | 4 | $117 |
| Atricure, Inc. | 3 | $115 |
| Novo Nordisk | 6 | $112 |
| Baxter Healthcare | 3 | $93 |
| Amgen | 4 | $90 |
| Boehringer Ingelheim | 3 | $56 |
| Irhythm Technologies, Inc. | 2 | $54 |
| Cardiva Medical, Inc. | 2 | $48 |
| AstraZeneca | 2 | $39 |
| Cardiofocus, Inc. | 1 | $30 |
| Kestra Medical Technology Services, Inc. | 1 | $30 |
| Preventice Services, LLC | 1 | $29 |
| Bardy Diagnostics, Inc. | 2 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $27 |
| Acutus Medical, Inc. | 1 | $27 |
| Merck | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Itamar Medical Inc | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanostim Leadleas Pacemaker$5,561
- Mitra Clip system$2,936
- RHYTHMIA$1,750
- Siello$625
- Accent Pacemaker$550
- Tendril Pacing Lead$550
- GENERAL - THERAPIES$374
- Micra$368
- Barostim Neo System$329
- Rhythmia Mapping System$250
- Quadra Assura CRT Defibrillator$155
- Reveal LINQ$143
- Carto 3 System$143
- MitraClip$138
- GENERAL EP$121
- RhythmVIEW Work Stations$114
- VIEWMATE$113
- IGT_D Systems$113
- AVEIR$111
- AURORA EV-ICD MRI SURESCAN$103
How this compares
$108,079 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 312 | $412,253 |
| XareltoRivaroxaban | 110 | $127,719 |
| EntrestoSacubitril/Valsartan | 32 | $35,559 |
| MultaqDronedarone Hcl | 11 | $8,582 |
| Flecainide Acetate | 108 | $3,954 |
| Metoprolol Succinate | 190 | $3,290 |
| SotalolSotalol Hcl | 152 | $2,756 |
| Propafenone Hcl | 13 | $2,106 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 51 | $2,019 |
| Dofetilide | 12 | $1,913 |
| Propafenone Hcl ErPropafenone Hcl | 11 | $1,596 |
| Sotalol AfSotalol Hcl | 40 | $827 |
| Valsartan | 12 | $700 |
| Amiodarone Hcl | 17 | $620 |
| Losartan Potassium | 64 | $615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $531 | $412,253312 claims |
| Johnson & JohnsonXarelto | $324 | $127,719110 claims |
| NovartisEntresto | $530 | $35,55932 claims |
| Sanofi-aventis U.S. LLCMultaq | $122 | $8,58211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in la Jolla
- Pam Taubla Jolla$3.2M
- Eric Topolla Jolla$2.2M
- Douglas Gibsonla Jolla$2.2M
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.